StockData

Nexgel vs Sensus Healthcare

NXGL and SRTS side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How NXGL and SRTS compare

Nexgel and Sensus Healthcare are about the same size, with market caps of $37.0M and $37.2M.

Nexgel grew revenue faster over the last twelve months (3.4% versus −53.3% for Sensus Healthcare).

Nexgel keeps more of each dollar of sales as profit, with a net margin of −51.3% compared with −96.5% at Sensus Healthcare.

Sensus Healthcare scores higher on the StockData Score (9 against 6 for Nexgel), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricNXGLSRTS
Size and price
Market cap$37.0M$37.2M
Share price$3.80$2.26
Change, 1 year−90.1%−47.7%
Change, 5 years–−63.5%
Beta (5Y)1.080.16
Employees1960
StockData Score
Total score69 (better)
Valuation score23 (better)
Growth score1 (better)0
Performance score1 (better)0
Health score26 (better)
Dividend score00
Valuation
P/S3.1×2.2× (better)
P/B7.5×1.0× (better)
FCF yield–−31.0%
Fair value$12.33$3.86
Margin of safety69.2% (better)41.4%
Growth
Revenue growth (TTM)3.4% (better)−53.3%
Revenue growth, 5Y average76.1% (better)23.5%
Profitability
Gross margin35.1%41.8% (better)
Operating margin−44.8% (better)−74.0%
Net margin−51.3% (better)−96.5%
FCF margin–−69.4%
Return on equity−129%−37.0% (better)
Return on invested capital−91.0%−39.5% (better)
Financial health
Debt / equity0.09 (better)0.00
Current ratio0.436.77 (better)
Altman Z-score−0.894.40 (better)
Piotroski F-score55
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions9.0%22.2%
Held by insiders13.2%13.3%
Insider net buying, 12 months$721K (better)$576K
Short interest, % of float–1.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.